论文部分内容阅读
目的研究BTB/POZ蛋白家族成员Kaiso在肺癌组织中的表达情况探讨其与临床病理参数、肺癌患者预后的相关性。方法应用免疫组织化学法检测Kaiso蛋白在100例原发性非小细胞肺癌组织(其中68例备有完整的预后资料)和30例相应癌旁肺组织中的表达情况,应用Westernblot的方法比较30例癌旁肺组织与配对肺癌组织中Kaiso相对表达量的差异。结果免疫组织化学染色表明Kaiso在正常支气管上皮细胞呈极微弱的浆表达,Westernblot检测结果表明肺癌组织中Kaiso蛋白的表达量显著高于正常肺组织的表达水平(n=30,P=0.000)。肺癌组织中浆阳性率为63.00%(63/100),Kaiso蛋白浆表达与高TNM分期(P=0.006)和淋巴结转移(P=0.004)成正相关。Kaiso蛋白浆表达与肺癌的不良预后有密切关系,阳性表达组术后5年生存率(22.22%)显著低于阴性组(64.00%,P=0.002,LogRank法)。Kaiso在细胞核中的阳性表达率仅为5.00%(5/100),但与临床病理因素无关。结论 Kaiso蛋白浆表达增强与肺癌患者的恶性表型及不良预后正相关。
Objective To investigate the expression of Kaiso in BTB / POZ protein family in lung cancer and its correlation with clinicopathological parameters and the prognosis of patients with lung cancer. Methods Immunohistochemical method was used to detect the expression of Kaiso protein in 100 cases of primary non-small cell lung cancer (68 cases with complete prognostic data) and 30 cases of corresponding paracancerous lung tissue. Western blot was used to compare 30 The difference of Kaiso relative expression between adjacent lung cancer tissues and matched lung cancer tissues. Results Immunohistochemical staining showed that Kaiso protein was expressed in very weak plasma in normal bronchial epithelial cells. The results of Western blot showed that the expression of Kaiso protein in lung cancer tissues was significantly higher than that in normal lung tissues (n = 30, P = 0.000). The positive rate of plasma in lung cancer tissues was 63.00% (63/100). There was a positive correlation between Kaiso protein expression and high TNM stage (P = 0.006) and lymph node metastasis (P = 0.004). The expression of Kaiso protein was closely related to the poor prognosis of lung cancer. The 5-year survival rate (22.22%) in the positive expression group was significantly lower than that in the negative group (64.00%, P = 0.002, LogRank method). The positive rate of Kaiso in the nucleus was only 5.00% (5/100), but not with clinicopathological factors. Conclusions The increased expression of Kaiso protein is positively correlated with malignant phenotype and poor prognosis in patients with lung cancer.